Abstract / Description of output
Revascularisation of ischaemic tissue remains an area of substantial unmet clinical need in cardiovascular disease. Strategies to induce therapeutic angiogenesis are therefore attractive. Our recent focus has been on human embryonic stem cell (hESC) strategies since hESC can be maintained in a pluripotent state or differentiated into any desired cell type, including endothelial cells (EC), under defined differentiation culture conditions. We recently published a protocol for non-good manufacturing practice (GMP) feeder- and serum-free hESC-EC-directed monolayer differentiation to vascular EC demonstrating the potential to generate hESC-derived EC in a GMP-compliant manner suitable for use in clinical trials. In this study we modified that laboratory protocol to GMP compliance. EC production was confirmed by flow cytometry, qRT-PCR and production of vascular structures in Matrigel®, yielding approximately 30 % mature VE-cadherin(+)/PECAM-1(+) cells using the GMP-compliant hESC line RC13. In conclusion, we have successfully demonstrated the production of vascular EC under GMP-compliant conditions suitable for clinical evaluation.
Original language | English |
---|---|
Pages (from-to) | 605-17 |
Number of pages | 13 |
Journal | Journal of cardiovascular translational research |
Volume | 5 |
Issue number | 5 |
DOIs | |
Publication status | Published - Oct 2012 |
Keywords / Materials (for Non-textual outputs)
- Antigens, CD
- Antigens, CD31
- Biomarkers
- Biotechnology
- Cadherins
- Cell Culture Techniques
- Cell Differentiation
- Cell Line
- Cell Lineage
- Embryonic Stem Cells
- Endothelial Cells
- Flow Cytometry
- Gene Expression Regulation, Developmental
- Guideline Adherence
- Guidelines as Topic
- Humans
- Ischemia
- Neovascularization, Physiologic
- Time Factors